Email

© 1 ih. gov< mailto IO nih. gov><mailto {MH nih.gov> [C] Olinger; Peter (NIH/NIAID) [E] Jahrlin, ike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis Subject: RE: Combining the existing Phase 1 with a Therapeutic Portion Dear All, At the request of Dr. Zeitlin in the email below, we would like to propose a teleconference this Friday (8/1/2014) at 7 AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST. Alternatively, we would propose a teleconference next Tuesday (8/5/2014) at 7 AM PDT/ 8 AM MDT/ 9 AM CDT/ 4 PM CEST if Friday is not an option for the group. Please let us know your availability and we will draft a preliminary agenda and distribute it to everyone along with dial-in information. Thank you, Marshall Marshall Hoke, B.A. Technical Associate CBR International Corp. (r) www.cbrintl.com<http://www.cbrintl.com><https://email.healthsystem.virginia.edu/owa/UrlBlockedError.aspx><http:/ /www.cbrintl.com/> This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are further requested to purge this electronic transmission and all copies thereof from your computer system. From: Larry Zeitlin [mailto {© mappbio.com] Sent: Wednesday, July 30, 2014 10:55 AM To: Trina Racine; deborah scott Cc: Frederick G *HS Hayden; Gary (Public Health Agency of Canada) Kobinger; HR © 1b. cov< mailto FO nin.gov><mailto FO nih.gov> [C] Olinger; Peter (NIH/NIAID) [E] Jahrling; Mike Hensley; Lisa (NIH/NIAID) [E] Hensley; Miles Brennan; Tara Nyhuis; Marshall Hoke Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion Hi all, This is coming together very nicely. I'd like to suggest a follow-up call to discuss this in more detail and have cc'd our colleagues at CBR who have been leading the regulatory and clinical planning effort for ZMapp. Assuming everyone agrees a call would be worthwhile, can I trouble CBR to arrange it? Best, Larry From: Trina Racine BE ¢ 2h 2c-2s0c.g¢.ca<maiito:trina racine@phac-aspc.gc.ca><mailtortrina.racine@ phacaspc.gc.ca>> Date: Wednesday, July 30, 2014 at 8:43 AM To: deborah scott (EEE © sbcclobal net<mailto ENO sbcelobal net><mailto EEO sbcglobal.net>> Ce: Frederick G *HS Hayden Ee bscmail.mce.virginia.edu<mailto {@hscmail.mcc.virginia.edu><mailto {fe hscmail.mcc.virginia.edu>>, Gary Kobinger <gary. kobinger @phac-aspc.gc.ca<mailto:gary.kobinger @phac-aspc.gc.ca><mailto:gary.kobinger@phacaspc.gc.ca>>, Gene Olinger {ENO nih.gov<mailto JH nih.gov><mailto JO nih.gov>>, Peter Jahrling <M© niaid.nih.gov<mailto fo niaid.nih.gov><mailto {MO niaid.nih.gov>>, Mike Hensley HO icloud.com<mailto fMH@ icloud.com><mailto f@icloud.com>>, Larry Zeitlin mappbio.com<mailto mappbio.com><mailto {© mappbio.com>>, Lisa Hensley gov<mailto: nih.gov><mailto {ENO nih.gov>> Subject: Re: Combining the existing Phase 1 with a Therapeutic Portion Hello all, I too have made a number of comments and edits. Please let me know if you would like to discuss. Trina